Lupin Moat Analysis: Score & Risks
Lupin Ltd.
A first-pass moat teardown of Lupin Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence.
Lupin Ltd. scores 5.47 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“In respiratory given that we have Xopenex®, we have a position in respiratory already. We can bring synergies through our development lifecycle management within our internal capabilities”
“Evolving portfolio and pipeline in Complex platforms and Specialty (Inhalation, Biosimilars and Injectables).”
“For the full year employee costs have increased 15.4% to INR 4,575 crores mainly driven by annual salary hikes, India field force expansion and forex translation.”
“Also, we are the only truly integrated player with the India cost advantage, having our own API, our own finished product. The other companies don't have the advantage that we do.”
“We are one of the few companies worldwide to obtain approval for generic versions of both Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) in the U.S. and EU markets”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion